EDGAR·FLOW

HERON THERAPEUTICS, INC. /DE/ — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 78/100
What the filing says
Heron Therapeutics agrees to sell substantially all assets of its pharmaceutical business (aprepitant/granisetron nausea products, bupivacaine/meloxicam pain products) to CorMedix Inc. for base cash consideration of $145 million, 14,583,333 shares of CorMedix common stock, plus royalty and earn-out payments (amounts redacted). Deal includes $2 million escrow and assumes specified liabilities. Requires Heron stockholder approval; CorMedix financing committed.
Why this rating

Asset sale of core business for ~$145M cash plus equity is material—likely 60%+ of Heron's $235M market cap. Transforms company into holding company; significant for trajectory but neutral pending stock price impact of CorMedix shares received and deal execution certainty.

Price action (we called it neutral)
before filing · preread
$0.38 ▲ 3.96%
at our read · unknown
$0.37
+10 min · unknown
$0.39 ▲ 5.42%
+30 min · unknown
$0.37 ▲ 1.36%
+1 hr · unknown
$0.39 ▲ 5.15%
+4 hrs · unknown
$0.38 ▲ 2.98%

The stock had already moved -3.81% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ HRTX · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.